Washington, D.C., partner Mercedes Meyer, presented in a panel at the American Conference Institute’s 7th National Conference on Life Sciences IP Due Diligence, January 20, 2010, in New York.  Her co-panelists were Paul Carango of Endo Pharmaceuticals and John Li of Novartis Biologics.  Her presentation, “Factoring Recent Developments in Life Sciences IP Case Law, Pending Patent Reform and Follow-on Biologics Legislation Into your Due Diligence Analysis,” covered recent court decisions and legislative proposals relating to patent law and follow-on biologics , and how these will affect analyses undertaken during IP due diligence, particularly for pharmaceutical, biotechnology, and medical device companies.